BDBM658036 3-(5-fluoro-2- methyl-6-oxo-1,6- dihydropyridin-3- yl)-1-(4-fluoro-2- methylphenyl)-6- (trifluoromethyl)- 2,3-dihydropyrido- [3,4-d]pyrimidin- 4(1H)-one::US20240083896, Example 11

SMILES Cc1cc(F)ccc1N1CN(C(=O)c2cc(ncc12)C(F)(F)F)c1cc(F)c(=O)[nH]c1C

InChI Key InChIKey=RQOVXEYWKZHQSW-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 658036   

TargetSodium channel protein type 5 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM658036(US20240083896, Example 11 | 3-(5-fluoro-2- methyl-...)
Affinity DataIC50: 316nMAssay Description:Pharmacological assessment of the compounds of the invention was performed using HEK293-Nav1.8 in combination with an assay developed on the QPatch 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2024
Entry Details
Go to US Patent